Prop1, Hesx1, Pou1F1, Lhx3 and Lhx4 Mutation and Deletion Screening and Gh1 P89l and Ivs3+1/+2 Mutation Screening in A Dutch Nationwide Cohort of Patients with Combined Pituitary Hormone Deficiency

L.C.G. Graaff, J. Argente, D.C.M. Veenma, M.L. Drent, A.G. Uitterlinden, A.C.S. Hokken-Koelega

Research output: Contribution to journalArticleAcademicpeer-review

31 Citations (Scopus)


Background/Aims: Mutation frequencies of genes involved in combined pituitary hormone deficiency (CPHD) vary substantially between populations. The HYPOPIT study aims to obtain an overall picture of known and new genetic defects and variations in a nationwide cohort of Dutch (mostly) sporadic CPHD patients. Methods: We screened 79 CPHD patients from 78 families (regardless of MRI and hormonal phenotype) for mutations and deletions in PROP1, HESX1, POU1F1, LHX3 and LHX4, as well as the P89L and IVS3+1/+2 mutations in GH1, recently described to cause pituitary hormone impairment in addition to GH deficiency. Results: We did not find any mutation or deletion in PROP1, HESX1, LHX3 or LHX4, nor GH1 P89L and GH1 IVS3+1/+2 mutations. Among 12 patients with a typical 'POU1F1 phenotype', 1 patient was formerly known to have a POU1F1 mutation. This results in a POU1F1 mutation frequency in these patients of 8.3%. Conclusion: Thorough screening for mutations and deletions in PROP1, HESX1, POU1F1, LHX3, LHX4, as well as screening for GH1 P89L or GH1 IVS3+1/+2 mutations, did not reveal any genetic defect in our cohort of CPHD patients except for one formerly known POU1F1 mutation in 1 patient. Future research should focus on alternative explanations for CPHD, like other genes or environmental factors. © 2010 S. Karger AG.
Original languageEnglish
Pages (from-to)363-371
JournalHormone Research in Paediatrics
Issue number5
Publication statusPublished - 2010

Cite this